Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Al Amri, Sawsan S ^a   Abbas, Ayman T ^a,b   Siddiq, Loai A ^a   Alghamdi, Abrar ^a   Sanki, Mohammad A ^c   Al Muhanna, Muhanna K ^d   Alhabbab, Rowa Y ^a   Azhar, Esam I ^a   Li, Xuguang ^e   Hashem, Anwar M ^a,f  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b MANSOURA UNIVERSITY   (Egypt)

^c KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^d KING ABDULAZIZ CITY FOR SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^e HEALTH CANADA   (Canada)

^f King Abdulaziz University   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CORONAVIRUS SPIKE GLYCOPROTEIN; DNA VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL; CAMEL; CHLOROCEBUS AETHIOPS; CORONAVIRUS INFECTION; DISEASE MODEL; FEMALE; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; SERODIAGNOSIS; VACCINE IMMUNOGENICITY; VERO CELL LINE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAMELUS; CERCOPITHECUS AETHIOPS; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGENICITY, VACCINE; IMMUNOGLOBULIN G; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NEUTRALIZATION TESTS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINES, DNA; VERO CELLS; VIRAL VACCINES;

EID: 85016136746     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep44875     Document Type: Article

References (52)

1. Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. & Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814-1820, doi: 10.1056/NEJMoa1211721 (2012).
2. Bermingham, A. et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro. Surveill. 17, 20290 (2012).
3. Pebody, R. G. et al. The United Kingdom public health response to an imported laboratory confrmed case of a novel coronavirus in September 2012. Euro. Surveill. 17, 20292 (2012).
4. Mackay, I. M. & Arden, K. E. MERS coronavirus: diagnostics, epidemiology and transmission. Virol. J. 12, 222, doi: 10.1186/s12985-015-0439-5 (2015).
5. Alraddadi, B. M. et al. Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Illness in Humans, Saudi Arabia, 2014. Emerg. Infect. Dis. 22, 49-55, doi: 10.3201/eid2201.151340 (2016).
6. Lessler, J. et al. Estimating the Severity and Subclinical Burden of Middle East Respiratory Syndrome Coronavirus Infection in the Kingdom of Saudi Arabia. Am. J. Epidemiol. 183, 657-663, doi: 10.1093/aje/kwv452 (2016).
7. Assiri, A. et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N. Engl. J. Med. 369, 407-416, doi: 10.1056/NEJMoa1306742 (2013).
8. Guery, B. et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet. 381, 2265-2272, doi: 10.1016/S0140-6736(13)60982-4 (2013).
9. Memish, Z. A., Zumla, A. I., Al-Hakeem, R. F., Al-Rabeeah, A. A. & Stephens, G. M. Family cluster of Middle East respiratory syndrome coronavirus infections. N. Engl. J. Med. 368, 2487-2494, doi: 10.1056/NEJMoa1303729 (2013).
10. Park, S. H. et al. Outbreaks of Middle East Respiratory Syndrome in Two Hospitals Initiated by a Single Patient in Daejeon, South Korea. Infect. Chemother. 48, 99-107, doi: 10.3947/ic.2016.48.2.99 (2016).
11. Hemida, M. G. et al. Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro. Surveill. 18, 20659 (2013).
12. Alagaili, A. N. et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio. 5, e00884-14, doi: 10.1128/mBio.00884-14 (2014).
13. Azhar, E. I. et al. Evidence for camel-to-human transmission of MERS coronavirus. N. Engl. J. Med. 370, 2499-2505, doi: 10.1056/NEJMoa1401505 (2014).
14. Müller, M. A. et al. MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983-1997. Emerg. Infect. Dis. 20, 2093-2095, doi: 10.3201/eid2012.141026 (2014).
15. Corman, V. M. et al. Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992-2013. Emerg. Infect. Dis. 20, 1319-1322, doi: 10.3201/eid2008.140596 (2014).
16. Falzarano, D. et al. Treatment with interferon-α 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 19, 1313-1317, doi: 10.1038/nm.3362 (2013).
17. Hart, B. J. et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J. Gen. Virol. 95, 571-577, doi: 10.1099/vir.0.061911-0 (2014).
18. Omrani, A. S. et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet. Infect. Dis. 14, 1090-1095, doi: 10.1016/S1473-3099(14)70920-X (2014).
19. de Wilde, A. H. et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J. Gen. Virol. 94, 1749-1760, doi: 10.1099/vir.0.052910-0 (2013).
20. Dyall, J. et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents. Chemother. 58, 4885-4893, doi: 10.1128/AAC.03036-14 (2014).
21. Ying, T. et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J. Virol. 88, 7796-7805, doi: 10.1128/JVI.00912-14 (2014).
22. Jiang, L. et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci. Transl. Med. 6, 234ra59, doi: 10.1126/scitranslmed.3008140 (2014).
23. Du, L. et al. A conformation-dependent neutralizing monoclonal antibody specifcally targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J. Virol. 88, 7045-7053, doi: 10.1128/JVI.00433-14 (2014).
24. Tang, X. C. et al. Identifcation of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc. Natl. Acad. Sci. USA 111, E2018-E2026, doi: 10.1073/pnas.1402074111 (2014).
25. Corti, D. et al. Prophylactic and postexposure efcacy of a potent human monoclonal antibody against MERS coronavirus. Proc. Natl. Acad. Sci. USA 112, 10473-10478, doi: 10.1073/pnas.1510199112 (2015).
26. Pascal, K. E. et al. Pre-and postexposure efcacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl. Acad. Sci. USA 112, 8738-8743, doi: 10.1073/pnas.1510830112 (2015).
27. Agrawal, A. S. et al. Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. Sci. Rep. 6, 31629, doi: 10.1038/srep31629 (2016).
28. Lu, G. et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 500, 227-2231, doi: 10.1038/nature12328 (2013).
29. Wang, L. et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun. 6, 7712, doi: 10.1038/ncomms8712 (2015).
30. Muthumani, K. et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci. Transl. Med. 7, 301ra132, doi: 10.1126/scitranslmed.aac7462 (2015).
31. Kim, E. et al. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine. 32, 5975-5982, doi: 10.1016/j.vaccine.2014.08.058 (2014).
32. Zhao, J. et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl. Acad. Sci. USA 111, 4970-4975, doi: 10.1073/pnas.1323279111 (2014).
33. Haagmans, B. L. et al. An orthopoxvirus-based vaccine reduces virus excretion afer MERS-CoV infection in dromedary camels. Science. 351, 77-81, doi: 10.1126/science.aad1283 (2016).
34. Guo, X. et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology. 145, 476-484, doi: 10.1111/imm.12462 (2015).
35. Song, F. et al. Middle East respiratory syndrome coronavirus spike protein delivered by modifed vaccinia virus Ankara efciently induces virus-neutralizing antibodies. J. Virol. 87, 11950-11954, doi: 10.1128/JVI.01672-13 (2013).
36. Coleman, C. M. et al. Purifed coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 32, 3169-3174, doi: 10.1016/j.vaccine.2014.04.016 (2014).
37. Agrawal, A. S. et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum. Vaccin. Immunother. 7, 1-6, doi: 10.1080/21645515.2016.1177688 (2016).
38. Du, L. et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 8, e81587, doi: 10.1371/journal.pone.0081587 (2013).
39. Yang, Y. et al. The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. Viral. Immunol. 27, 543-550, doi: 10.1089/vim.2014.0080 (2014).
40. Mou, H. et al. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efciently elicits neutralizing antibodies. J. Virol. 87, 9379-9383, doi: 10.1128/JVI.01277-13 (2013).
41. Ma, C. et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-the importance of immunofocusing in subunit vaccine design. Vaccine. 32, 6170-6176, doi: 10.1016/j.vaccine.2014.08.086 (2014).
42. Lan, J. et al. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS One 9, e112602, doi: 10.1371/journal.pone.0112602 (2014).
43. Deming, D. et al. Vaccine efcacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS. Med. 3, e525, doi: 10.1371/journal.pmed.0030525 (2006).
44. Honda-Okubo, Y. et al. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J. Virol. 89, 2995-3007, doi: 10.1128/JVI.02980-14 (2015).
45. Iwata-Yoshikawa, N. et al. Effects of Toll-like receptor stimulation on eosinophilic infltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J. Virol. 88, 8597-8614, doi: 10.1128/JVI.00983-14 (2014).
46. Weingartl, H. et al. Immunization with modifed vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Vi rol. 78, 12672-12676 (2004).
47. Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS. One. 7, e35421, doi: 10.1371/journal.pone.0035421 (2012).
48. Jaume, M. et al. SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong. Kong. Med. J. 18, Suppl 2 31-6 (2012).
49. Coleman, C. M. & Frieman, M. B. Growth and Quantifcation of MERS-CoV Infection. Curr. Protoc. Microbiol. 37, 15E.2.1-9, doi: 10.1002/9780471729259.mc15e02s37 (2015).
50. Hashem, A. M. et al. CD40 ligand preferentially modulates immune response and enhances protection against infuenza virus. J. Immunol. 193, 722-734, doi: 10.4049/jimmunol.1300093 (2014).
51. Tang, J. et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum. Vaccin. Immunother. 11, 1244-1250, doi: 10.1080/21645515.2015.1021527 (2015).
52. Yang, Z. Y. et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 428, 561-564 (2004).